Could IMU ultimately be worth $500m?, page-9

  1. Mer
    234 Posts.
    lightbulb Created with Sketch.  4
    Still a risky buy IMO until this trial is thumbs up and over. Safety has been based on low doses and small numbers, it's quite possible a side-effect has remained hidden through pure dumb luck. I'm thinking of the cardiotoxicity that crops up with Herceptin.

    The 2nd cohort may have started. Higher doses and different patients. I still think a nasty side-effect would rate a get together with the scientists, especially if it threatened to derail things - eg cardiac.

    The must exist the possibility that the immune memory could leave some patients with a chronic autoimmune problem.

    Despite my concerns, I hold and wait. Just not with the certainty that a lot of HC bods seem to have.

    cheers
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.